Prediction of invasive adenocarcinomas manifesting as pure ground-glass nodules based on radiomic signature of low-dose CT in lung cancer screening

Abstract

Objective: To develop a radiomic model based on low-dose CT (LDCT) to distinguish invasive adenocarcinomas (IAs) from adenocarcinoma in situ/minimally invasive adenocarcinomas (AIS/MIAs) manifesting as pure ground-glass nodules (pGGNs) and compare its performance with conventional quantitative and semantic features of LDCT, radiomic model of standard-dose CT, and intraoperative frozen section (FS). Methods: A total of 147 consecutive pathologically confirmed pGGNs were divided into primary cohort (43 IAs and 60 AIS/MIAs) and validation cohort (19 IAs and 25 AIS/MIAs). Logistic regression models were built using conventional quantitative and semantic features, selected radiomic features of LDCT and standard-dose CT, and intraoperative FS diagnosis, respectively. The diagnostic performance was assessed by area under curve (AUC) of receiver operating characteristic curve, sensitivity, and specificity. Results: The AUCs of quantitative-semantic model, radiomic model of LDCT, radiomic model of standard-dose CT, and FS model were 0.879 (95% CI, 0.801-0.935), 0.929 (95% CI, 0.862-0.971), 0.941 (95% CI, 0.876-0.978), and 0.884 (95% CI, 0.805-0.938) in the primary cohort and 0.897 (95% CI, 0.768-0.968), 0.933 (95% CI, 0.815-0.986), 0.901 (95% CI, 0.773-0.970), and 0.828 (95% CI, 0.685-0.925) in the validation cohort. No significant difference of the AUCs was found among these models in both the primary and validation cohorts (all p > 0.05). Conclusion: The LDCT-based quantitative-semantic score and radiomic signature, with good predictive performance, can be pre-operative and non-invasive biomarkers for assessing the invasive risk of pGGNs in lung cancer screening. Advances in knowledge: The LDCT-based quantitative-semantic score and radiomic signature, with the equivalent performance to the radiomic model of standard-dose CT, can be pre-operative predictors for assessing the invasiveness of pGGNs in lung cancer screening and reducing excess examination and treatment.